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Abstract: The dystroglycan (DG) expression pattern can be altered in severe muscular dystrophies. In fact, some congeni-
tal muscular dystrophies (CMDs) and limb-girdle muscular dystrophies (LGMDs) are caused by point mutations identi-
fied in six glycosyltransferase genes which are likely to target different steps along the posttranslational “O-glycosylation 
route” leading to a fully decorated and functional -DG subunit. Indeed, hypoglycosylation of -DG is thought to repre-
sent a major pathological event, in that it could reduce the DG’s ability to bind the basement membrane components, thus 
leading to sarcolemmal instability and necrosis. In order to set up an efficient standard immunological protocol, taking 
advantage of a wide panel of antibodies, we have analyzed the two DG subunits in a small cohort of adult dystrophic pa-
tients, whom an extensive medical examination had already clinically classified as affected by LGMD (5), Miyoshi (1) or 
distal (1) myopathy. Immunofluorescence analysis of skeletal muscle tissue sections revealed a proper sarcolemmal local-
ization of the DG subunits in all the patients analyzed. However, Western blot analysis of lectin enriched skeletal muscle 
samples revealed an abnormal glycosylation of -DG in two patients. Our work reinforces the notion that a careful immu-
nological and biochemical analysis of the two DG subunits should be always considered as a prerequisite for the identifi-
cation of new putative cases of dystroglycanopathy. 
Keywords: Dystroglycan, limb-girdle muscular dystrophy, distal myopathy, Miyoshi myopathy, secondary dystrogly-
canopathies, dystrophin-glycoprotein complex. 
INTRODUCTION 
The dystrophin-glycoprotein complex (DGC) represents 
a group of cytoskeletal, transmembrane and peripheral pro-
teins linking the extracellular matrix to the actincytoskeleton 
in a wide variety of human tissues, ranging from muscle 
(skeletal,cardiac or smooth) to central and peripheral nervous 
system, as well as the airways, lung or kidney epithelia [1]. 
Dystroglycan (DG) is the pivotal component of the DGC and 
is thought to play a crucial role in skeletal muscle, affecting 
both sarcolemmal stability and the post-synaptic elements at 
the neuromuscular junctions (MNJs) crucial for innervations 
[2]. The DG adhesion complex is composed of two subunits, 
- and -DG. -DG is a membrane-associated extracellular 
matrix glycoprotein that binds with high affinity the extracel-
lular matrix laminin and proteoglycans (perlecan, agrin and 
biglycan), whereas -DG spans the membrane and links -
DG to the cytoskeleton via either dystrophin or utrophin [1].  
Deletion of the DG gene in knockout mice resulted in 
early embryonic lethality [3] whilst DG expression could be  
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“secondarily” altered in many other types of muscular dys-
trophy, including Duchenne muscular dystrophy [4, 5]. In 
particular, -DG can lose its typical sarcolemmal targeting 
in dystrophin- and sarcoglycan-deficient muscle sarcolem-
mas, and DG expression was shown to be largely influenced 
in congenital muscular dystrophy type 1A [1, 6-8]. 
Recently, several forms of congenital muscular dystrophy 
have been linked to mutations in putative and demonstrated 
glycosyltransferases or accessory proteins of glycosyltrans-
ferases which are thought to be specifically involved in the 
posttranslational O-glycosylation pathway of -DG [9]. In 
most cases, these disorders feature a marked alteration in the 
glycosylation pattern of -DG and therefore are commonly 
referred to as secondary dystroglycanopathies [9]. To date, at 
least 8 genes have been linked to these disorders, namely the 
glycosyltransferases Protein-O-mannosyl transferase 1 
(POMT1), Protein-O-mannosyl transferase 2 (POMT2) and 
Protein-O-mannose 1,2-N-acetylglucosaminyltransferase 1 
(POMGnT1), three enzymes whose functions remain un-
characterized, Fukutin, Fukutin-related protein (FKRP) and 
LARGE, and two subunits (DPM1 and DPM2) of dolichol-
phosphate-mannose (Dol-P-Man) synthase [9, 10] (see Table 
1).  
Adding to the complexity of dystroglycan-linked neuro-
muscular disorders, mutations in glycosyltransferase genes 
also cause muscular dystrophy displaying a later onset such 
as limb-girdle muscular dystrophies (LGMD) (Table 1) [9]. 
LGMDs are a group of clinically and genetically heteroge-Analysis of Dystroglycan in Dystrophic Patients  The Open Neurology Journal, 2011, Volume 5    69 
neous disorders characterized by weakness and wasting of 
pelvic and shoulder girdle musculatures. The clinical course 
of LMGDs varies from severe forms with early onset and 
rapid progression within the first decade of life, to milder 
forms with later onset and slower progression [11]. Several 
forms of LGMDs are due to mutations in members of the 
DGC, as sarcoglycans. Five forms of LGMDs (LGMD2I, 
LGMD2K, LGMD2L, LGMD2M, LGMD2N) are character-
ized by secondary hypoglycosylation of -DG (Table 1) [12-
16]. Also genetic abnormalities of dysferlin, a sarcolemmal 
protein involved in membrane repair, may cause both 
LGMD2B and Miyoshi distal myopathy [17]. It should be 
noted that no genetic abnormalities of the six genes encoding 
the O-glycosyltransferases have been linked so far to distal 
myopathies. Interestingly, the first human primary dystro-
glycanopathy associated to LGMD and cognitive impair-
ment, featuring a DG “core protein” missense mutation 
(Thr192Met) hitting the N-terminal portion of -DG [18], 
has been very recently identified [19]. Following an exten-
sive characterization, the authors suggest that the mutated 
site may influence the efficiency of binding and action of the 
LARGE glycosyltransferase, leading to a misdecorated -
DG [19]. Moreover, in a forward genetic approach aimed at 
finding novel genes involved in congenital muscle diseases, 
a zebrafish dystroglycan mutant hitting the C-terminal do-
main of -DG was also identified, underlying the possibility 
of a primary involvement of dystroglycan in muscular dys-
trophies [20]. 
It is often quite difficult to distinguish between the vari-
ous forms of LGMDs and distal myopathies. The diagnosis 
relies on a combination of immunohistochemical and im-
munoblot analysis followed by DNA sequencing for the 
identification of the primary gene involved. In this study we 
analyzed the DG subunits, - and -DG, in a small cohort of 
seven patients that have all been classified as affected by 
non-congenital muscular dystrophies by clinical examina-
tion, in order to assess the possible involvement of DG in 
LGMDs and distal myopathy phenotypes. Such an analysis 
can be particularly useful in order to pave the way for estab-
lishing a more standardized clinical and diagnostic assess-
ment of the DG complex. 
MATERIALS AND METHODOLOGY 
Patients 
Patients were diagnosed according to clinical observa-
tions, family history and serum creatine kinase (CK) levels. 
Muscle biopsies were obtained with informed consent. 
Immunofluorescence of Skeletal Muscle Biopsies 
Five unfixed serial cryosections, 10μm thick, were ob-
tained from each muscle biopsy. After blocking of unspecific 
sites with blocking buffer (0.5% Triton X-100, 1% BSA in 
PBS) for 30 minutes at room temperature, the sections were 
incubated with the primary antibodies overnight at 4°C in a 
humid chamber. After washing in PBS, the sections were 
incubated with the appropriated fluorescent secondary anti-
body for 30 minutes at room temperature. All tissue sections 
were mounted in aqueous mountant and viewed with a fluo-
rescence microscope (Nikon), images collected exploiting a 
Table 1.  Congenital Muscular Dystrophies (CMD) and Limb-Girdle Muscular Dystrophies (LGMD) Characterized by Hypoglyco-
sylation of -DG  
Designation OMIM  Gene  Protein 
CMD
* 
MDC1C 60661  FKRP  Fukutin-related  protein 
MDC1D 608840 LARGE  Acetylglucosaminyltransferase-like  protein 
Fukuyama CMD  253800  FCMD  Fukutin 
Muscle-Eye-Brain disease (MEB)  253280  POMGnT1 
O-linked mannose 1,2N- 
acetylglucosaminyltransferase 
Walker-Warburg syndrome (WWS)  236670 
POMT1 
POMT2 
O-mannosyl-transferase 
LGMD 
LGMD2I 607155  FKRP;  DPM3 
Fukutin-related protein; 
Dolichyl-phosphate mannosyltransferase poly-
peptide 3 
LGMD2K 609308  POMT1  O-mannosyl-transferase 
LGMD2L 611307  FCMD  Fukutin 
LGMD2M 611588 POMGnT1 
O-linked mannose 1,2N- 
acetylglucosaminyltransferase 
LGMD2N 613158  POMT2  O-mannosyl-transferase 
*Very recently, mutations in DPM2 were associated to a form of CMD characterised by severe cognitive impairment, early-onset myoclonic epilepsy and cerebellar hypoplasia [9, 
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digital Nikon camera (Coolpix 5400) using the software X-
Pro. 
Electrophoresis and Western Blot Analysis of Muscle 
Biopsies 
Muscle biopsies from dystrophic patients and control 
sample were homogenized in lysis buffer (125mM Tris-HCl 
pH 7.4, 2mM EDTA, 1% SDS, 1% Triton X-100) containing 
protease inhibitors; supernatants (total protein extract) were 
collected upon centrifugation. Proteins were separated by 
SDS-PAGE and transferred to nitrocellulose (NT) mem-
branes. After blocking with 5% dry milk Tris-buffered saline 
(TTBS; 150 mM NaCl, 10 mM Tris-HCl buffer pH 7.4 and 
0.05% Tween 20), the NT membranes were incubated o/n at 
4°C with primary antibody. After washing in TTBS and in 
TTBS containing 3% milk powder for 30 min, the blots were 
incubated for 1 h with anti-mouse or anti-rabbit antibodies 
horseradish peroxidase-conjugated (Pierce). 
After washing in 3% milk powder TTBS and several 
washes in TTBS, blots were developed using enhanced 
chemiluminescence (ECL) (Pierce). The immuno-reacting 
bands were visualized by exposing the membranes to Kodak 
X-OMAT films. Glycoprotein enrichment was performed on 
total protein extracts. Briefly, supernatants were incubated 
with Wheat Germ Lectin (WGL) Sepharose 6MB (Amer-
sham) overnight at 4°C. After extensive washing with wash-
ing buffer (WB) (50mM Tris-HCl pH 7.8, 500mM NaCl, 
0.1% Triton X-100), bound glycoprotein were eluted in WB 
with 250mM N-acetylglucosamine and used in Western blot. 
Antibodies 
In Western blot and in immunofluorescence experiments, 
-DG was detected with mouse monoclonal antibodies anti-
-DG 43DAG/8D5 (Novocastra) diluted 1:25 and anti--DG 
BD (Becton Dickinson) diluted 1:500. -DG was detected 
with mouse monoclonal antibodies anti--DG clone VIA4-1 
(lot 32685, Upstate Biotechnology) and clone IIH6 (lot 
Table 2.  Summary of Clinical and Genetic Features of Patients 
Patient/ 
Sex 
Age 
onset 
Family 
hystory 
CK level 
(times nor-
mal) 
Age 
at biopsy 
Respiratory 
function 
Cardiac 
function 
Physical examination 
(Clinical diagnosis) 
Genetic 
Analysis 
P1/M 30  No  3-5x  27  N  N  Weakness of gastroc-
nemii and posterior 
thigh muscles (Distal 
myopathy) 
CAPN3,FKRP 
DYSF, TCAP, 
LMNA: normal 
P2/F  10 Yes 1-1.5x  48  N  Coronary 
artery 
disease 
Proximal lower limb 
weakness with quad-
riceps and calf hyper-
trophy. Scapular 
winging, mild facial 
and upper limb weak-
ness (LGMD) 
CAPN3, -SGC, 
FKRP, LMNA, 
Fukutin, 
POMT1: 
normal 
P3/M 35  No  15-40x  24  N  N  Severe distal lower 
limb weakness, mild 
lower limb weakness 
(Miyoshi myopathy) 
Mutations in 
DYSF
* 
P4/M 30-35  Yes  3-5x  35  N  N  Calf hypotrophy, 
scapular winging, 
upper girdle weak-
ness. Pes cavus 
(LGMD) 
Only the brother 
was analysed: 
CAPN3, 
FKRP, DYSF, 
TCAP, LMNA, 
FKTN, POMT1: 
normal 
P5/F 18  No  10-15x  33  N  N Proximal and distal 
weakness in the four 
limbs with distal 
onset (LGMD) 
Mutation in 
DYSF
** 
P6/F  NA  No NA 27 N N NA  (LGMD)  NA 
P7/F 25-30  Yes  10-40x  30  N  N  Weakness and calf 
hypotrophy, then 
proximal spreading 
(LGMD) 
Mutations in 
DYSF
*** 
N= normal. 
NA= not available. 
* mutations: exon 21 1966 A>G (K656Q) + exon 23 2220_2205delins T fs X17 (T734S). 
**mutation: exon 50 5626 G>A (D1876N). 
***mutations: exon 27 2875 C>T (R959W). Analysis of Dystroglycan in Dystrophic Patients  The Open Neurology Journal, 2011, Volume 5    71 
22991 Upstate Biotechnology) diluted 1:500 and 1:200, re-
spectively. Polyclonal antibodies directed against the mouse 
-DG C-terminal region previously characterized [21] were 
used at dilution 1:100. 
RESULTS 
Clinical Examination of Patients 
Three male and four female patients affected by non-
congenital muscle dystrophies were studied. Age at onset 
was on average 25 years (range 10-35 years), and the aver-
age age at biopsy 32 years (range 24-48 years). Three pa-
tients, P2, P4 and P7, reveal a positive family history; on 
detail, P4 and P7 have one brother affected respectively, 
whereas P2 has one brother and one sister affected. The 
creatin kinase level was analyzed and the values were within 
a range of 1 to 40 times the normal value. In particular, P1 
underwent biopsy before showing increased levels of creatin 
kinase. 
All patients had a normal respiratory and cardiac func-
tion, with the exception of P2 who was affected by a coro-
nary artery disease.  
Some patients were also genetically characterized. In par-
ticular, the calpain (CAPN3), dysferlin (DYSF), telethonin 
(TCAP), lamin (LMNA), -sarcoglyan (-SGC), fukutin, 
POMT1 and fukutin related protein (FKRP) genes were ana-
lyzed. Among the genes analyzed, only P3, P5 and P7 dis-
played mutations in the dysferlin gene. The clinical details 
and genetic analysis outcome are reported in Table 2. 
Immunofluorescence Analysis of the Dystroglycan Com-
plex 
Immunofluorescence analysis of the DG subunits was 
performed on skeletal muscle cryosections of all patients, 
with the exception of P4, using a panel of antibodies hitting 
different epitopes within the - and -DG subunits, as de-
picted in Fig. (1). The -DG subunit was stained with two 
different antibodies hitting the extracellular region (BD) and 
the cytoplasmic domain of the protein (43-DAG). The -DG 
signal in all the samples analyzed was comparable with the 
control section, and showed normal sarcolemma expression 
(Fig.  2). Also the membrane localization of the -subunit 
was normal when detected with a polyclonal antibody raised 
against the core protein of the C-terminal domain of -DG: 
furthermore, the positive staining with an antibody raised 
against the carbohydrate molecules revealed the correct gly-
cosylation of the -subunit in all patients (Fig. 2). 
 
Fig. (2). Immunofluorescence localization of - and -DG in hu-
man skeletal muscle sections. C: control, P1-P7: patients. The -
DG subunit was detected with two monoclonal antibodies, 
43DAG/8D5 and BD, that recognized the -DG cytoplasmic tail 
and its extracellular domain, respectively. -DG was detected with 
the monoclonal antibody IIH6 (lot 22991), raised against an unde-
fined carbohydrate epitope (red arrow), and with a polyclonal anti-
body directed against its C-terminal region. 
Western Blot Analysis of Total Protein Extracts 
The - and -DG subunits were also analyzed by West-
ern blot using total skeletal muscle protein extracts. -DG 
was probed with the monoclonal antibody VIA4-1 (Upstate), 
that recognises a yet unidentified carbohydrate epitope. The 
expected broad band of approximately 156 kDa was present 
in the control sample and in patients P1, P2, P3 and P7 
(Fig. 3A, red arrow). The patient P5 displays a strong signal 
 
 
 
 
 
 
 
 
 
Fig. (1). Scheme of the DG subunits displaying the epitopes recognized by different antibodies. 72     The Open Neurology Journal, 2011, Volume 5  Pavoni et al. 
for  -DG but with a slight shift toward lower molecular 
mass (Fig. 3A). On the contrary, in patients P4 and P6 the 
156 kDa band of -DG was totally absent (Fig. 3A, red as-
terisk), although in P6 a very faint band around 120 kDa was 
also detected that could represent a hypoglycosylated form of 
-DG still recognized by the antibody. -DG was analyzed 
in total protein extracts using the monoclonal antibody 
NCL-43DAG that recognizes the last 15 aa of its cytoplas-
mic tail. All the samples analyzed showed the expected 43 
kDa band (Fig. 3B). 
 
Fig. (3). Western blot analysis of the DG subunits in total protein 
extracts from patients P1-P7 and from control muscle tissue (C). A: 
Samples were resolved with a 7.5-15% acrylamide gradient SDS-
PAGE and -DG was detected with the antibody VIA4-1 (lot 
32685) raised against an undefined carbohydrate epitope (red   
arrow). In samples P4 and P6 the expected 156 KDa band was ab-
sent (red asterisk). The additional lower bands detected in all the 
samples might correspond to hypoglycosylated and/or proteolytic 
forms of -DG; B: Western blot upon a 12% SDS-PAGE of the 
total protein extracts using anti 43DAG/8D5 for -DG detection. 
All the samples showed the expected 43 kDa band. 
Western Blot Analysis of Lectin-Enriched Extracts from 
Patients P4 and P6 
The total protein extracts of patients P4 and P6, which 
showed an anomalous signal of -DG in Western blot, were 
submitted to a lectin-enrichment protocol using wheat germ 
lectin (WGL) beads that specifically bind to N-
acetylglucosamine residues. This protocol is very useful for 
the analysis of the carbohydrate decorations of a glycopro-
tein like -DG. In the normal tissue sample, WGL-enriched 
fractions contain both - and -DG subunits (Fig. 4A). The 
WGL-enriched fractions from patients P4 and P6, analyzed 
with an antibody against -DG, showed a loss of immunode-
tection in comparison to the corresponding total protein ex-
tract (Fig. 4B). 
DISCUSSION 
Primary and Secondary Dystroglycanopathies: An In-
creasingly Complex Scenario Ranging from Congenital 
to Limb-Girdle Muscular Dystrophies 
In this study, we have analyzed the - and -DG subunits 
in seven patients who had been catalogued by clinical obser-
vation as subjects affected by non-congenital muscular dys-
trophies (Table 2). Five of those patients were classified as 
affected by LGMD, one by distal myopathy and another one 
by Miyoshi myopathy. 
We have used a combination of immunofluorescence and 
immunoblot analysis to characterize the DG complex and to 
determine whether an alteration of the DG expression pattern 
emerged in any of these patients affected by non-congenital 
muscular dystrophies. Firstly, we analyzed the dystroglycan 
subunits expressed in skeletal muscle by immunofluores-
 
Fig. (4). Western blot analysis of total protein extracts of control 
and patients P4 and P6 that were submitted to a lectin-enrichment 
protocol using wheat germ lectin beads. A: In the control tissue 
sample, WGL-enriched fractions contain both the -DG and -DG 
subunits. B: WGL-enriched fractions from patients P4 and P6, ana-
lysed with antibodies against -DG. -DG, that is present in the 
total protein extracts of both patients, is not enriched upon WGL 
incubation, confirming the presence of altered glycosylation of -
DG. Analysis of Dystroglycan in Dystrophic Patients  The Open Neurology Journal, 2011, Volume 5    73 
cence of tissue sections, using antibodies hitting different 
epitopes within the two molecules (Fig. 1). In particular, the 
-DG subunit was stained using two monoclonal antibodies 
directed against its extracellular domain and its cytosolic C-
terminal domain, respectively (Fig. 2 ), while the -DG 
subunit was detected using a polyclonal antibody raised 
against the core protein at the level of its C-terminal domain, 
[21], and by a monoclonal antibody directed against an un-
known carbohydrate epitope of -DG (Mab IIH6 purchased 
from Upstate) (Fig. 2). 
In all patients, all the different antibodies detected the 
expected membrane localization of the DG subunits (Fig. 2). 
From these very experiments, the DG complex does not 
seem to be related at all to the dystrophic phenotypes ob-
served in those patients. However, Western blot analysis of 
crude muscle protein extracts, performed using a different 
monoclonal antibody directed against a carbohydrate epitope 
of  -DG (Mab VIA4-1, purchased from Upstate), showed 
the loss of -DG immunodetection in patients P4 and P6, 
while patient P5 displayed a signal with a slight shift toward 
a lower molecular mass (Fig. 3A). 
The discrepancy between the immunofluorescence and 
Western blot analysis may find an explanation in the possi-
bility that -DG glycosylation is indeed altered in these pa-
tients, and the carbohydrate epitope recognized by the VIA4-
1 antibody is missing or is reduced. It should be noted that 
-DG does not lose its sarcolemmal targeting, so it could be 
hypothesized that the altered glycosylation may rather affect 
its functional properties [22]. Such a picture seems to be 
confirmed by the lectin enrichment protocol that failed to co-
purify -DG from total protein extracts of P4 and P6 patients 
(Fig. 4B). In fact, the complete loss of immunodetection of 
the  -DG subunit in P4 and P6 WGL-enriched samples 
should depend on the impaired interaction between -DG 
and the lectin, which in itself depends on the presence of N-
acetylglucosamine residues in the mucin-like region of -
DG (Fig. 3A) [22]. 
Therefore, P4 and P6 patients may well be affected by a 
form of “dystroglycanopathy” that could be related to the 
reduced amount of N-acetylglucosamine present within the 
glycosylation shell of -DG. Being POMGnT1 the glycosyl-
transferase that typically add the N-acetylglucosamine 
“brick” to the growing O-mannose sugar chains, these two 
patients (P4 and P6) could be tentatively catalogued as 
LGMD2M, even if muscle weakness displayed a distal in-
volvement as well. Moreover, the patient P6 revealed also a 
deficit of calpain-3 (data not shown) that is characteristic of 
LGMD2A. Further genetic analysis will be essential to test 
this hypothesis and to identify directly and unambiguously 
the mutated gene responsible of the altered glycosylation of 
-DG. 
The Importance of an Extensive Immunological Analysis 
of the Two Dystroglycan Subunits for Clinical Diagnosis 
Our analysis of a small cohort of patients revealed that 
the biochemical characterization of patients affected by mus-
cular dystrophy should include a more extensive immu-
nological analysis of muscle samples using different antibod-
ies. 
In fact, muscle sections of all the patients showed in im-
munofluorescence the same expression and targeting pattern 
of the two DG subunits. On the other hand, when applying 
Western blot analysis, especially upon lectin-enrichment, 
two patients were unambiguously identified as patients dis-
playing an altered glycosylation pattern of -DG. Although 
the possible role of POMGnT1 in a form of LGMD also with 
distal involvement could be only speculated, these patients 
should now undergo an extensive gene analysis aiming at a 
definitive characterization of the genes responsible for their 
pathologies. 
After the identification of DG as a common final target 
for a whole series of glycosyltransferases responsible for its 
O-glycosylation pattern, the DG complex has taken centre 
stage in neuromuscular medicine [9]. Nonetheless, many 
important structural and functional details of the DG com-
plex, in the light of its involvement in human neuromuscular 
disorders, await further elucidation. In particular, the novel 
identification of a pathogenic missense mutation in the DG 
gene that results in neuromuscular abnormalities, points to 
the opportunity of including DAG1 in the list of genes whose 
mutations cause muscular dystrophy and cognitive impair-
ment in humans [19, 23].  
Moreover, it has not been clarified yet whether DG 
would represent the substrate of other still unidentified en-
zymes. In fact, there are several reported cases in which pa-
tients, while displaying a series of phenotypic signs that 
would suggest the presence of a secondary dystroglycanopa-
thy, do not carry mutations in any of the glycosyltransferases 
identified so far [9]. It is also possible that additional un-
known substrates of these enzymes exist, enlarging the 
pathological scenario of sarcolemmal instability and necrosis 
[23]. 
During the next few years, further efforts will certainly 
be needed in order to identify alternative biochemical and/or 
genetic pathways underlying this group of congenital and 
limb-girdle muscular dystrophies. 
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